| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5578660 | Journal of Pain and Symptom Management | 2016 | 24 Pages |
Abstract
ACL is associated with worse fatigue and QOL and may not differ significantly between cancer and noncancer patients nearing end of life. SM drugs are more responsible for ACL in cancer and noncancer patients, although DM drugs contribute significantly to ACL in the latter group. We recommend more attention to reducing anticholinergic use in all patients with life-limiting illness.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Michael J. BS, Arif H. MD, MHS, Steven P. MS, Greg P. PhD, David C. BMed, MPH, FRACP, Amy P. MD, PhD, Thomas W. MD, MA,